Department of Surgery, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China.
PeerJ. 2023 Mar 17;11:e15034. doi: 10.7717/peerj.15034. eCollection 2023.
We previously showed that higher SARS-CoV-2 viral load correlated with smaller thyroid volumes among COVID-19 survivors at 2 months after acute COVID-19. Our current follow-up study evaluated the evolution of thyroid volumes and thyroiditis features within the same group of patients 6 months later.
Adult COVID-19 survivors who underwent thyroid ultrasonography 2 months after infection (USG1) were recruited for follow-up USG 6 months later (USG2). The primary outcome was the change in thyroid volume. We also reassessed thyroiditis features on USG, thyroid function and anti-thyroid antibodies.
Fifty-four patients were recruited (mean age 48.1 years; 63% men). The mean thyroid volume increased from USG1 to USG2 (11.9 ± 4.8 to 14.5 ± 6.2 mL, < 0.001). Thirty-two patients (59.3%) had significant increase in thyroid volume by ≥15%, and they had a median increase of +33.3% (IQR: +20.0% to +45.0%). Multivariable logistic regression analysis showed that only higher baseline SARS-CoV-2 viral load independently correlated with significant thyroid volume increase on USG2 ( = 0.022). Among the seven patients with thyroiditis features on USG1, six (85.7%) had the features resolved on USG2. None had new thyroiditis features on USG2. All abnormal thyroid function during acute COVID-19 resolved upon USG1 and USG2.
Most COVID-19 survivors had an increase in thyroid volume from early convalescent phase to later convalescent phase. This increase correlated with high initial SARS-CoV-2 viral load. Together with the resolution of thyroiditis features, these may suggest a transient direct atrophic effect of SARS-CoV-2 on the thyroid gland with subsequent recovery of thyroid volume and thyroiditis features.
我们之前的研究表明,在急性 COVID-19 后 2 个月的 COVID-19 幸存者中,较高的 SARS-CoV-2 病毒载量与较小的甲状腺体积相关。我们目前的随访研究评估了同一组患者在 6 个月后甲状腺体积和甲状腺炎特征的演变。
招募在感染后 2 个月(USG1)进行甲状腺超声检查的成年 COVID-19 幸存者进行 6 个月后的后续 USG(USG2)。主要结局是甲状腺体积的变化。我们还重新评估了 USG 上的甲状腺炎特征、甲状腺功能和抗甲状腺抗体。
招募了 54 名患者(平均年龄 48.1 岁;63%为男性)。甲状腺体积从 USG1 增加到 USG2(11.9 ± 4.8 至 14.5 ± 6.2 mL,<0.001)。32 名患者(59.3%)甲状腺体积增加≥15%,中位数增加+33.3%(IQR:+20.0%至+45.0%)。多变量逻辑回归分析显示,只有较高的基线 SARS-CoV-2 病毒载量与 USG2 上的显著甲状腺体积增加独立相关(=0.022)。在 USG1 上有甲状腺炎特征的七名患者中,有六名(85.7%)在 USG2 上特征消失。在 USG2 上没有新的甲状腺炎特征。急性 COVID-19 期间所有异常的甲状腺功能在 USG1 和 USG2 时均恢复正常。
大多数 COVID-19 幸存者从早期恢复期到后期恢复期甲状腺体积增加。这种增加与初始 SARS-CoV-2 病毒载量高相关。与甲状腺炎特征的缓解一起,这可能表明 SARS-CoV-2 对甲状腺有短暂的直接萎缩作用,随后甲状腺体积和甲状腺炎特征恢复。